Mersana Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio4.367.5922.0010402.132201.35
P/B Ratio-18.587.586.353.677.99
Price/Tangible Book7.586.353.677.99
Enterprise Value Ratios
EV/Revenue1.311.9912.486408.311894.81
Profitability & Returns
Return on Equity (ROE)-5.05%-2.66%-1.91%-0.97%-0.57%
Return on Assets (ROA)-0.25%-0.38%-0.47%-0.44%-0.29%
Return on Invested Capital (ROIC)-1.02%-1.07%-0.88%-0.52%-0.33%
Return on Capital Employed (ROCE)-0.89%-1.05%-0.84%-1.06%-0.36%
Leverage & Solvency Ratios
Debt/Equity-3.010.920.400.320.07
Liquidity Ratios
Current Ratio2.193.363.493.988.62
Quick Ratio2.153.293.403.748.50
Efficiency Ratios
Asset Turnover0.220.130.100.000.00
Yield & Distribution Ratios
Earnings Yield-0.39%-0.61%-0.35%-0.38%-0.05%
FCF Yield-0.47%-0.61%-0.09%-0.31%-0.04%
Buyback Yield-0.06%-0.24%-0.33%-0.15%-0.41%